CRIS Current Research Information System

GHELLI LUSERNA DI RORÀ, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.578
NA - Nord America 3.421
EU - Europa 2.335
AF - Africa 201
SA - Sud America 146
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.692
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.352
VN - Vietnam 1.197
SG - Singapore 928
CN - Cina 740
GB - Regno Unito 572
IT - Italia 354
DE - Germania 295
SE - Svezia 274
HK - Hong Kong 217
FR - Francia 144
IN - India 135
NL - Olanda 129
RU - Federazione Russa 106
BR - Brasile 99
CH - Svizzera 88
IE - Irlanda 82
JP - Giappone 70
FI - Finlandia 66
BD - Bangladesh 61
KR - Corea 52
CI - Costa d'Avorio 48
ZA - Sudafrica 48
TG - Togo 46
CA - Canada 45
EE - Estonia 45
BE - Belgio 39
BG - Bulgaria 35
NG - Nigeria 33
UA - Ucraina 30
PH - Filippine 26
JO - Giordania 22
ES - Italia 20
AR - Argentina 18
TH - Thailandia 18
IQ - Iraq 15
PL - Polonia 13
TW - Taiwan 13
MX - Messico 12
SC - Seychelles 12
TR - Turchia 12
AT - Austria 11
ID - Indonesia 11
PK - Pakistan 11
UZ - Uzbekistan 10
GR - Grecia 8
IR - Iran 8
EC - Ecuador 7
PY - Paraguay 6
AU - Australia 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
EU - Europa 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
DZ - Algeria 3
HR - Croazia 3
IL - Israele 3
JM - Giamaica 3
KZ - Kazakistan 3
LB - Libano 3
LT - Lituania 3
MK - Macedonia 3
RS - Serbia 3
VE - Venezuela 3
AL - Albania 2
CO - Colombia 2
CR - Costa Rica 2
CY - Cipro 2
CZ - Repubblica Ceca 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PA - Panama 2
TM - Turkmenistan 2
TN - Tunisia 2
AO - Angola 1
BO - Bolivia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MM - Myanmar 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
Totale 9.687
Salva come PNG Salva come JPEG
Città #
Singapore 690
Southend 509
Ashburn 393
Chandler 335
Dong Ket 325
Fairfield 236
San Jose 213
Hong Kong 206
Ho Chi Minh City 174
Hanoi 169
Ann Arbor 164
Houston 127
Beijing 123
Wilmington 123
Seattle 120
Woodbridge 119
Cambridge 93
Hefei 93
Santa Clara 91
Boardman 88
Princeton 88
Dublin 82
Bologna 81
Bern 76
New York 65
Tokyo 61
Nanjing 49
Abidjan 48
Lomé 46
Westminster 44
Seoul 43
Los Angeles 42
Lauterbourg 41
Padova 41
Helsinki 40
Da Nang 39
Brussels 38
Dallas 35
Munich 35
Sofia 35
Medford 33
Haiphong 32
Frankfurt am Main 30
Berlin 26
Buffalo 26
Falls Church 26
Abeokuta 25
Jinan 25
Redondo Beach 24
Amman 21
Redwood City 21
São Paulo 21
Milan 20
Shanghai 20
Bremen 19
Nanchang 19
Saint Petersburg 19
Turku 19
London 17
Toronto 17
Shenyang 16
Guangzhou 15
Rome 15
Changsha 14
Hebei 14
Hải Dương 14
Biên Hòa 13
Jiaxing 13
Chicago 12
Council Bluffs 12
Hyderabad 12
Montreal 12
Paris 12
Phoenix 11
Mountain View 10
Redmond 10
San Diego 10
Turin 10
Brooklyn 9
Falkenstein 9
Hangzhou 9
Salamanca 9
San Francisco 9
Warsaw 9
Zhengzhou 9
Amsterdam 8
Florence 8
Norwalk 8
Quezon City 8
The Dalles 8
Vienna 8
Baghdad 7
Bengaluru 7
Düsseldorf 7
Orem 7
Verona 7
Atlanta 6
Bình Phước 6
Can Tho 6
Chennai 6
Totale 6.275
Salva come PNG Salva come JPEG
Nome #
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 324
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 308
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 277
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 257
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 254
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 240
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 236
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 229
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 223
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 218
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 215
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 214
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 212
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 211
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 208
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 207
Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients 207
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 204
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 197
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 197
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 193
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 193
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 193
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 193
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 189
The cell cycle checkpoint inhibitors in the treatment of leukemias 187
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 186
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 185
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 182
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 180
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 179
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 179
Clec12a: A new AML stem cell-associated antigen 178
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 174
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 172
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 164
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 164
You have accessMine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs 160
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 153
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 151
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 147
Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions 147
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 143
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies 141
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 140
The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias 131
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 125
The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway 115
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 106
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 90
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia 83
null 75
Totale 9.886
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.351
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.351
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022972 108 34 55 82 97 55 22 47 40 61 188 183
2022/20231.248 148 170 66 173 99 87 30 55 186 34 82 118
2023/2024376 12 46 27 42 23 80 18 41 21 15 19 32
2024/20251.279 38 172 101 92 114 52 148 66 6 151 61 278
2025/20263.406 293 213 215 221 335 162 404 125 866 295 146 131
2026/202766 66 0 0 0 0 0 0 0 0 0 0 0
Totale 9.886